Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.
MedCity News
Read about new developments from Stellar Health, Paige, venBio, and more.
Shares0
Stellar Health is pleased to announce the appointment of JoRel Nye, former Senior Vice President of Technical Product Management at Aledade as its new Chief Product Officer.
Stellar Health is a point-of-care, cloud-based platform that helps primary care providers continually engage with their patients by providing them real-time information and tangible action-based incentives for improving quality of care. Stellar Health’s mission is to enable all providers to engage and succeed in VBC by bridging the incentive gap between providers and payors. To read more,
Paige co-founder Dr. David Klimstra has been named Chief Medical Officer, a role that will start in August. Klimstra is currently Chair of the Department of Pathology at Memorial Sloan Kettering Cancer Center. In his new role, Klimstra will lead the clinical implementation and evidence generation for Paige’s technology and
Actinium Pharmaceuticals Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company, is developing antibody radiation-conjugates (ARCs) to combine the .